Woodline Partners LP Has $4.11 Million Position in XOMA Co. (NASDAQ:XOMA)

Woodline Partners LP increased its position in XOMA Co. (NASDAQ:XOMA - Free Report) by 63.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 156,266 shares of the biotechnology company's stock after buying an additional 60,927 shares during the quarter. Woodline Partners LP owned about 1.33% of XOMA worth $4,107,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of XOMA. New York State Common Retirement Fund boosted its position in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 800 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 1,183 shares in the last quarter. Bank of America Corp DE lifted its stake in XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in XOMA during the fourth quarter worth approximately $206,000. Finally, Rhumbline Advisers boosted its holdings in XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock worth $291,000 after buying an additional 1,699 shares in the last quarter. Institutional investors own 95.92% of the company's stock.

Insider Transactions at XOMA

In other XOMA news, CIO Bradley Sitko acquired 4,134 shares of XOMA stock in a transaction that occurred on Friday, March 21st. The stock was purchased at an average cost of $23.89 per share, with a total value of $98,761.26. Following the purchase, the executive now owns 10,484 shares in the company, valued at approximately $250,462.76. The trade was a 65.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Joseph M. Limber acquired 17,935 shares of the firm's stock in a transaction on Thursday, April 3rd. The shares were acquired at an average price of $25.24 per share, with a total value of $452,679.40. Following the completion of the transaction, the director now directly owns 16,524 shares in the company, valued at approximately $417,065.76. This trade represents a -1,271.08% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 29,312 shares of company stock valued at $735,061 over the last quarter. Company insiders own 9.10% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $104.00 price objective on shares of XOMA in a research report on Wednesday. Benchmark assumed coverage on XOMA in a research report on Thursday, April 17th. They set a "buy" rating and a $35.00 target price on the stock. Finally, Wall Street Zen upgraded XOMA from a "sell" rating to a "hold" rating in a research report on Friday, April 11th.

XOMA Trading Up 1.5%

Shares of XOMA stock traded up $0.38 during trading hours on Thursday, reaching $25.53. 25,553 shares of the stock traded hands, compared to its average volume of 30,871. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $305.52 million, a PE ratio of -7.40 and a beta of 0.89. XOMA Co. has a 1-year low of $18.35 and a 1-year high of $35.00. The business has a fifty day moving average price of $22.76 and a 200 day moving average price of $25.18.

XOMA (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.32. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $15.91 million for the quarter, compared to analysts' expectations of $6.75 million. On average, equities research analysts forecast that XOMA Co. will post -1.41 EPS for the current year.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.